Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial
| Autor: | Tomonori Hirashima, Makoto Maemondo, Tetsuya Mitsudomi, Toshiaki Takahashi, Nobuyuki Yamamoto, Masayoshi Noshiro, Tomohide Tamura, Makoto Nishio, Nobuyuki Katakami, Myung-Ju Ahn, Hiroshige Yoshioka, Shiro Akinaga, Sang-We Kim, Kazuhiko Nakagawa, Chun-Ming Tsai, Koichi Azuma, Keunchil Park |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Wild type Phases of clinical research Pharmacology Placebo respiratory tract diseases stomatognathic diseases chemistry.chemical_compound chemistry Internal medicine Medicine Erlotinib Tivantinib business Previously treated neoplasms medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 32:8044-8044 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 8044 Background: A randomized phase II study suggested that adding a c-Met inhibitor tivantinib (T) to an EGFR-TKI erlotinib (E) may prolong PFS in non-squamous NSCLC patients (pts) with 1-2 prior ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|